BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY) has selected Interpublic Group (NYSE:IPG) as its global agency partner for creative, production, and media services for its Consumer Health division. The partnership will manage marketing activities for major brands including Aspirin, Bepanthen, Claritin, and Canesten.
The integrated agency approach aims to leverage GenAI tools and capabilities to enhance consumer engagement at the local level while maintaining global consistency. The new structure is designed to improve media buying power and deliver personalized content across markets. The partnership is set to go live on January 1, 2026, following a transition period.
Bayer (OTC:BAYRY) has announced a strategic distribution partnership with Mint Pharmaceuticals Inc. for ADALAT® XL® 30 mg tablets in Canada, effective September 3, 2025. The collaboration aims to enhance the accessibility of ADALAT® XL®, a medication indicated for chronic stable angina and mild to moderate essential hypertension management.
The partnership leverages Mint's 15-year experience in supply chain management and extensive distribution network in the Canadian market. ADALAT® XL®, which received its initial market authorization in Canada in 1995, will benefit from Mint's established infrastructure to ensure consistent availability to healthcare providers and patients across Canada.
Bayer (OTC:BAYRY) will present new data for KERENDIA® (finerenone) at the upcoming HFSA Annual Scientific Meeting in Minneapolis, September 26-29, 2025. The presentations will include two key subgroup analyses from the Phase III FINEARTS-HF trial examining treatment effects across heart failure duration and in patients with high medication burden.
The company will also present retrospective real-world data on guideline-directed medical therapy treatment patterns for newly diagnosed heart failure patients in the U.S. This follows the FDA's July 2025 approval of KERENDIA's new indication for treating adult patients with heart failure with left ventricular ejection fraction ≥40%. The drug was previously approved in July 2021 for reducing cardiovascular and kidney disease risks in adult patients with CKD associated with T2D.
Bayer (OTC:BAYRY) has announced significant progress in its dual approach to treating Parkinson's disease through both cell and gene therapies. The company has initiated two major clinical trials: the Phase III exPDite-2 trial for bemdaneprocel (cell therapy) and the Phase II REGENERATE-PD trial for AB-1005 (gene therapy).
The trials focus on treating moderate-stage Parkinson's disease, which affects over 10 million people globally. Bemdaneprocel aims to replace lost dopamine-producing cells, while AB-1005 explores gene therapy potential. The REGENERATE-PD trial is currently active in the UK, Poland, and USA, with Germany to follow.
These developments are being conducted through Bayer's subsidiaries, BlueRock Therapeutics LP and AskBio Inc., showcasing the company's comprehensive end-to-end approach in cell and gene therapy development.
Bayer (OTC:BAYRY) has announced the expansion of its "Take Care, Now" campaign in partnership with country star Luke Bryan and Feeding America®, marking their 10-year collaboration anniversary. The campaign addresses food insecurity and "hidden hunger" in rural America through multiple initiatives.
The campaign features a social media initiative #HeresToTheFarmer, where Bayer will donate up to 1 million meals through Feeding America for each hashtag share. The initiative includes food drives at Luke Bryan's Farm Tour 2025 locations, with stops in Wisconsin, Illinois, and Michigan.
Recent research reveals concerning trends: 90% of Americans have modified shopping habits due to rising food prices, with rural families experiencing a 12-point decline in food quality compared to urban areas. To date, Bayer has provided over 10 million meals through the campaign and helped 3.4 million mothers and babies through their partnership with Vitamin Angels.
Bayer (OTC:BAYRY) announced that the FDA has accepted its New Drug Application (NDA) for gadoquatrane, a novel low-dose contrast agent for magnetic resonance imaging (MRI). The contrast agent is designed for imaging the central nervous system and other body regions in both adults and pediatric patients, including neonates.
The submitted dose of 0.04 mmol gadolinium per kilogram body weight represents a 60% reduction in gadolinium compared to current macrocyclic gadolinium-based contrast agents (GBCAs). The submission is supported by positive data from the Phase III QUANTI studies, and similar applications are under review in Japan, the European Union, and other countries.
Monsanto (OTC:BAYRY) has announced agreements in principle to resolve PCB-related litigation cases involving over 200 plaintiffs from the Sky Valley Education Center in Washington state. The settlement excludes nine prior adverse verdicts (involving 49 plaintiffs) that remain under appeal.
The settlement costs are covered by the PCB litigation provision taken in Q2 2025. The company is pursuing a strategy to contain litigation risks by the end of 2026 and has filed a complaint in Missouri to enforce indemnity contracts signed in 1972 by former electrical manufacturing customers.
Bayer (OTC:BAYRY) has announced the U.S. launch of Aspirina, its leading pain relief product in Mexico, targeting the growing Hispanic market. The strategic expansion aims to serve the Hispanic population, which currently represents 19% of the U.S. population and is projected to reach 28% by 2060.
Aspirina holds impressive market metrics in Mexico, including a 99% awareness rate and 67% regular consumer usage. The product will be available at select Walmart and Walgreens locations, leveraging Bayer's 125-year legacy in aspirin manufacturing and the strong cultural connection among Hispanic consumers, with 70% maintaining strong ties to their country of origin.
Summary not available.
PPG (NYSE: PPG) reported record net sales of approximately $17.7 billion for 2022, marking a 5% increase from 2021, fueled by an 8% rise in organic sales due to higher prices. The company announced its 51st consecutive annual dividend hike, continuing a 123-year streak of uninterrupted payments. Key environmental achievements included a 13% reduction in greenhouse gas emissions and an investment of $16.2 million in nonprofit support, particularly in STEM education. CEO Tim Knavish expressed optimism for future growth as the economic environment improves, emphasizing cash generation and margin management. Shareholder actions included the re-election of directors and approval of executive compensation practices.